Recurring concern

Inadequate controls for combined sedative medication toxicity

Pin Get email alerts Request correction

First reported 8 Aug 2018•Latest report 29 Dec 2025

Definition

What this concern includes

Includes failures of controls specifically intended to prevent, detect or respond to toxicity from combining prescribed and non-prescribed sedative medicines, multiple sedating medicines, or sedative medicines with excess alcohol, including interaction guidance, patient warnings, prescribing and quantity safeguards, monitoring, follow-up and escalation.

Not included

  • Excludes general medication prescribing, administration, supply or monitoring failures where combined sedative toxicity is not the identified unsafe condition.
  • Excludes access to dangerous or prescription-only medicines where the concern is unauthorised supply or excessive quantity rather than toxicity from combining sedative substances.
  • Excludes single-medicine adverse effects and non-sedative medication interactions unless the assertion explicitly concerns the same combined-sedative toxicity hazard.
  • Excludes treatment of established overdose or intoxication after the combined-sedative toxicity risk was reliably recognised and escalated.
Reports
5

Distinct published reports

Individual concerns
7

A report can raise multiple concerns

Date range
2018–2025

First to latest report issue date

Stated actions
16

Described in published responses

Reports over time

Reports over time

Reports about this concern issued each year.

* 2026 is projected from reports observed to 7 Sep 2026.

Most frequent recipients

Most frequent recipients

Reports about this concern sent to each recipient.

Department of Health and Social Care2
Medicines and Healthcare products Regulatory Agency2
Barts Health NHS Trust1
BNF Publications1
Hilltops Medical Centre1
NHS Central East Integrated Care Board1
NHS England1
Northamptonshire Healthcare NHS Foundation Trust1

Concerns and responses across reports

Only concerns grouped under this recurring concern are included. Select any concern, action or position to view the source wording.

  1. Cambridgeshire and Peterborough

    AI-generated summary

    Fallon Leanne ADAMS · Prevention of Future Deaths report

    This summary was generated using AI from the published report. Please read the original report for the complete account.

    Report summary

    Fallon Leanne Adams was found unresponsive and cold in her cell at HMP Peterborough on 9 February 2023 and was declared deceased after CPR and a negative heart trace. The inquest concluded that she died from intoxication by mixed drugs, with illicitly obtained medication having a high probability of causing her death. Concerns included the combined sedative effects of prescribed and non-prescribed medication, a lack of specific warnings about over-sedation and death, and inadequate welfare checks and observations.

    Read the report on judiciary.uk

    Source evidence

    How this individual concern was interpreted

    PFD Monitor created a concise, searchable interpretation from the report wording shown below.

    PFD Monitor interpretation

    Potential for over-sedation and death from combined sedative medications

    Wider context from the report

    “• Whilst an inmate at HMP Peterborough Fallon ADAMS was prescribed methadone (for opiate withdrawal) and chlordiazepoxide (for alcohol withdrawal). She also took non-prescribed ████████ apparently obtained from an illicit source within the prison. All of these medications have a sedative effect which in combination have the potential to cause over sedation and death. • The evidence seemed to show that at no stage was Ms ADAMS given a specific warning or advice stating that taking additional non-prescribed medication ████████ could result in over sedation and death. • I also heard evidence in relation to Regulation 28 issues. Whilst it is clear that a number of relevant changes were being made it was not clear that a specific warning in relation to the risks of over sedation was being implemented. ”

    Source location

    Fallon Leanne ADAMS · Prevention of Future Deaths report
    Page 3 · concerns

    Open source report

    Source evidence

    How this individual concern was interpreted

    PFD Monitor created a concise, searchable interpretation from the report wording shown below.

    PFD Monitor interpretation

    Failure to provide and implement specific warnings about the risks of over-sedation from additional non-prescribed medication

    Wider context from the report

    “• Whilst an inmate at HMP Peterborough Fallon ADAMS was prescribed methadone (for opiate withdrawal) and chlordiazepoxide (for alcohol withdrawal). She also took non-prescribed ████████ apparently obtained from an illicit source within the prison. All of these medications have a sedative effect which in combination have the potential to cause over sedation and death. • The evidence seemed to show that at no stage was Ms ADAMS given a specific warning or advice stating that taking additional non-prescribed medication ████████ could result in over sedation and death. • I also heard evidence in relation to Regulation 28 issues. Whilst it is clear that a number of relevant changes were being made it was not clear that a specific warning in relation to the risks of over sedation was being implemented. ”

    Source location

    Fallon Leanne ADAMS · Prevention of Future Deaths report
    Page 3 · concerns

    Open source report

    Source evidence

    How this respondent action was interpreted

    PFD Monitor created a concise, searchable interpretation from the published response wording shown below.

    PFD Monitor interpretation

    Remind secure-environment prescribers to discuss medication purposes, risks, interactions, follow-up, and document contemporaneous consultation advice.

    Verbatim wording from the response

    “We agree it is important that a patient is informed about the risk(s) of any medication(s) our clinicians prescribe, including those that may arise from interactions with other medications they may be taking, whatever the source.”

    Source location

    Response from Northamptonshire Healthcare Foundation Trust
    Page 2 · response
    Published 5 January 2026

    Open published response

    Source evidence

    How this respondent action was interpreted

    PFD Monitor created a concise, searchable interpretation from the published response wording shown below.

    PFD Monitor interpretation

    Remind prescribing clinicians to assess and manage cumulative sedative burden, recognise oversedation, repeat unexpected observations, document findings and escalation decisions, and escalate concerns proactively.

    Verbatim wording from the response

    “In response to your Report, we have reminded our prescribing clinicians of our expectations concerning the assessment and management of cumulative sedative burden, recognition of over-sedation, and the need for proactive escalation where concerns are identified.”

    Source location

    Response from Northamptonshire Healthcare Foundation Trust
    Page 3 · response
    Published 5 January 2026

    Open published response

    Source evidence

    How this respondent action was interpreted

    PFD Monitor created a concise, searchable interpretation from the published response wording shown below.

    PFD Monitor interpretation

    Introduce and routinely provide patients with a harm-minimisation leaflet covering polypharmacy, illicit substances, substance use alone, reduced tolerance, and medication initiation or titration risks.

    Verbatim wording from the response

    “We have also introduced a new harm minimisation advice leaflet, which is now routinely provided to patients. This leaflet clearly outlines key risks, including polypharmacy, the use of illicit drugs alongside prescribed medication, the dangers of using substances alone in cells (particularly overnight), reduced tolerance following periods of abstinence, and the increased risk associated with medication initiation and titration periods.”

    Source location

    Response from Northamptonshire Healthcare Foundation Trust
    Page 3 · response
    Published 5 January 2026

    Open published response

  2. County Durham and Darlington

    AI-generated summary

    Sean Benjamin CRAWFORD · Prevention of Future Deaths report

    This summary was generated using AI from the published report. Please read the original report for the complete account.

    Report summary

    Sean Benjamin CRAWFORD died on 18 December 2020 in Darlington from the combined toxic effect of alcohol and clozapine, neither being individually at toxic levels. The principal concern was that available guidance and medication packaging warned about alcohol, sedation and potentially dangerous side effects but did not advise that death could result from this combination.

    Read the report on judiciary.uk

    Source evidence

    How this individual concern was interpreted

    PFD Monitor created a concise, searchable interpretation from the report wording shown below.

    PFD Monitor interpretation

    Failure of clozapine packaging and leaflets to warn that combined use with alcohol may cause death

    Wider context from the report

    “The circumstances in which Sean came by his death, the combined effects of clozapine with alcohol, seems to be, statistically, very rare. None of the professionals who gave evidence in this case could cite a death with the same cause of death as that suffered by Sean. This said, clozapine is a well-established medication whose side effects are well known. It was originally developed in the 1960s. It is well-known that it requires careful management and monitoring. The side effects are recognised ones and widely known. None of the professional witnesses expressed any lack of familiarity with it or its side effects. One of these side effects is sedation. Likewise, obviously, alcohol is a recognised central nervous system depressant. This is a death from Central Nervous System Depression, consequent to a comparatively high level of clozapine and a comparatively high level of ethanol in the blood – neither individually fatal. It is evident that there is no guidance in any academic literature, British National Formulary, or NICE or MHRA advices on the dangers of death in this scenario. It is noticeable that the leaflet that comes with the Clozaril (clozapine) packages clearly states that it must not be taken with alcohol, and the evidence to me was that the medication comes with a further label, in a similar vein, on the packaging. Neither, however, advises of death being a possibility. All the literature advises that sedation is a potentially dangerous side effect of clozapine. Death from Central Nervous System Depression, over-sedation, is not uncommon. It is often associated with alcohol, and other substance, use. ”

    Source location

    Sean Benjamin CRAWFORD · Prevention of Future Deaths report
    Page 2 · concerns

    Open source report

    Source evidence

    How this individual concern was interpreted

    PFD Monitor created a concise, searchable interpretation from the report wording shown below.

    PFD Monitor interpretation

    Lack of guidance on the risk of death from combined clozapine and alcohol use

    Wider context from the report

    “The circumstances in which Sean came by his death, the combined effects of clozapine with alcohol, seems to be, statistically, very rare. None of the professionals who gave evidence in this case could cite a death with the same cause of death as that suffered by Sean. This said, clozapine is a well-established medication whose side effects are well known. It was originally developed in the 1960s. It is well-known that it requires careful management and monitoring. The side effects are recognised ones and widely known. None of the professional witnesses expressed any lack of familiarity with it or its side effects. One of these side effects is sedation. Likewise, obviously, alcohol is a recognised central nervous system depressant. This is a death from Central Nervous System Depression, consequent to a comparatively high level of clozapine and a comparatively high level of ethanol in the blood – neither individually fatal. It is evident that there is no guidance in any academic literature, British National Formulary, or NICE or MHRA advices on the dangers of death in this scenario. It is noticeable that the leaflet that comes with the Clozaril (clozapine) packages clearly states that it must not be taken with alcohol, and the evidence to me was that the medication comes with a further label, in a similar vein, on the packaging. Neither, however, advises of death being a possibility. All the literature advises that sedation is a potentially dangerous side effect of clozapine. Death from Central Nervous System Depression, over-sedation, is not uncommon. It is often associated with alcohol, and other substance, use. ”

    Source location

    Sean Benjamin CRAWFORD · Prevention of Future Deaths report
    Page 2 · concerns

    Open source report

    Source evidence

    How this respondent action was interpreted

    PFD Monitor created a concise, searchable interpretation from the published response wording shown below.

    PFD Monitor interpretation

    Conduct a further assessment of clozapine product information on drug-drug interactions and consider improvements for healthcare professionals, patients, families and carers.

    Verbatim wording from the response

    “We have considered the evidence provided and the circumstances leading to Mr Crawford’s death. We have also recently met with a member of Mr Crawford’s immediate family to discuss their concerns. Some of these relate to clinical discussions between a patient and their prescriber which we are not able to address, as it is not within our remit to comment on the clinical care in specific cases. However, because of the nature of some of the concerns raised, we intend to conduct a further assessment of the information provided within the clozapine product information regarding drug-drug interactions. As part of this assessment, we will be giving careful consideration to the information which is provided to healthcare professionals, patients and their families and carers, and whether this can be improved.”

    Source location

    Response from Medicine and Healthcare products Regulatory Agency
    Page 2 · response
    Published 22 February 2024

    Open published response

    Source evidence

    How this respondent action was interpreted

    PFD Monitor created a concise, searchable interpretation from the published response wording shown below.

    PFD Monitor interpretation

    Work with the British National Formulary as the clozapine assessment progresses.

    Verbatim wording from the response

    “We are aware that you have also written to the BNF, and we will work with them as our assessment progresses. In the meantime, we will continue to closely monitor the safety of clozapine, including cases of drug-drug interactions. Should any updates to the product information be required we will issue an article in our bulletin to healthcare professionals “Drug Safety Update” accordingly.”

    Source location

    Response from Medicine and Healthcare products Regulatory Agency
    Page 2 · response
    Published 22 February 2024

    Open published response

    Source evidence

    How this respondent action was interpreted

    PFD Monitor created a concise, searchable interpretation from the published response wording shown below.

    PFD Monitor interpretation

    Review and revise pharmacodynamic interaction wording on sedative and CNS-depressant risks in BNF messages and tables.

    Verbatim wording from the response

    “To address the concerns raised in your report, we plan to review the wording around the use of drugs that cause sedation (including clozapine and alcohol) and drugs with CNS depressant effects (including alcohol) within the pharmacodynamic interaction messages and in the tables. This will further highlight that concurrent use of two or more drugs that can cause sedation and / or CNS depression might increase the risk of CNS depressant effects, such as sedation, unconsciousness, coma, respiratory depression, and cardiovascular depression, and / or enhance the effects of drugs with CNS depressant effects. In addition, the pharmacodynamic interaction tables have now been added to the online versions of the BNF and BNFC ensuring this content is more accessible to users.”

    Source location

    Response from BNF
    Page 1 · response
    Published 22 February 2024

    Open published response

    Source evidence

    How this respondent action was interpreted

    PFD Monitor created a concise, searchable interpretation from the published response wording shown below.

    PFD Monitor interpretation

    Add pharmacodynamic interaction tables to online BNF and BNFC versions.

    Verbatim wording from the response

    “The BNF includes information on pharmacodynamic interactions, that is interactions between drugs which have similar or antagonistic pharmacological effects or side-effects. This information is present within interaction messages of relevant drug monographs in online versions of the BNF and the BNF app. The same information is presented in tables in print editions of the BNF, but at the time of this death, these tables were not present in online versions of the BNF or in the BNF + BNFC app.”

    Source location

    Response from BNF
    Page 1 · response
    Published 22 February 2024

    Open published response

    Source evidence

    How this respondent action was interpreted

    PFD Monitor created a concise, searchable interpretation from the published response wording shown below.

    PFD Monitor interpretation

    Share the coroner’s report with NICE for consideration of its findings in published guidance.

    Verbatim wording from the response

    “should not be taken due to the potential harm to the patient. Departmental officials, however, have shared your report with NICE, so it can consider the impact of your findings on its published guidance.”

    Source location

    Response from Department of Health and Social Care
    Page 2 · response
    Published 22 February 2024

    Open published response

    Source evidence

    How this respondent position was interpreted

    PFD Monitor created a concise, searchable interpretation from the published response wording shown below.

    PFD Monitor interpretation

    MHRA is responsible for assessing and potentially improving clozapine product information about drug interactions and associated safety risks.

    Verbatim wording from the response

    “I am aware that the Medicines & Healthcare products Regulatory Agency (MHRA) has provided a response in respect of the key concern you raise in the report. As you will be aware, MHRA is an executive agency of the Department of Health and Social Care (DHSC) with responsibility for the regulation of medicinal products in the UK. The MHRA ensures that medicines are efficacious and acceptably safe, and that any possible side effects which have been reported to occur with use of a medicine are appropriately described in the authorised product information. However, MHRA has recognised in the response that none of the authorised product information specifically mention any risk of death because of the interaction with alcohol.”

    Source location

    Response from Department of Health and Social Care
    Page 2 · response
    Published 22 February 2024

    Open published response

    Source evidence

    How this respondent position was interpreted

    PFD Monitor created a concise, searchable interpretation from the published response wording shown below.

    PFD Monitor interpretation

    NICE is responsible for considering whether the report’s findings should affect published guidance on clozapine and alcohol risks.

    Verbatim wording from the response

    “In preparing this response, Departmental officials have made enquiries with National Institute for Health and Care Excellence (NICE). The National Institute for Health and Care Excellence (NICE) is the independent body responsible for developing authoritative, evidence-based guidance on best practice for the health and care system. NICE guidelines are developed by experts based on a thorough assessment of the available evidence and through extensive engagement with stakeholders. Healthcare professionals are expected to take them into full account in their decision making, although it is important to note that NICE guidelines are not mandatory and do not override a clinician’s responsibility to make decisions appropriate to individual patients.”

    Source location

    Response from Department of Health and Social Care
    Page 1 · response
    Published 22 February 2024

    Open published response

  3. Milton Keynes

    AI-generated summary

    Jacqueline Sharman CAMPBELL · Prevention of Future Deaths report

    This summary was generated using AI from the published report. Please read the original report for the complete account.

    Report summary

    Jacqueline Sharman CAMPBELL was found collapsed at home after living with chronic back pain for more than 20 years and taking multiple prescribed medicines. The inquest concluded that she likely inadvertently overdosed on tramadol, which in combination with other medicines had a synergistic effect causing respiratory depression and death. The principal concern was the safety risk of polypharmacy involving gabapentinoids and opioids, particularly their cumulative and synergistic effects on the central nervous system.

    Read the report on judiciary.uk

    Source evidence

    How this individual concern was interpreted

    PFD Monitor created a concise, searchable interpretation from the report wording shown below.

    PFD Monitor interpretation

    Severe risk of cumulative and synergistic central nervous system depression from gabapentinoid and opioid polypharmacy

    Wider context from the report

    “Her GP, ████████, gave clear and candid evidence. I accept the management of patients who describe intractable debilitating pain is challenging and difficult and that requests for other or increasing doses of medication can be difficult to resist. ████████ agreed that the prescribing of the various drugs identified had potential to be dangerous. He told me that after a certain point the benefits of increasing or adding doses or medications in terms of pain relief were minimal. This scenario seems to be an on individuals one for GP’s and patients alike. ████████ told me that subsequent to Ms Campbell’s death the practice had convened and discussed the circumstances and agreed on regular reviews for patients taking these sorts of medication. There were no plans identified to actively look for these patients and to work to rationalize and / or reduce their medications. I am of the view that polypharmacy including gabapentinoids and opiates represents a severe safety risk in patients with a iatrogenic drug dependency. I consider that the risk in individuals like Ms Campbell of an inadvertent overdose of medications which have a cumulative and synergistic effect to depress the central nervous system can easily become extreme and lead to death. There have been a number of deaths in the Milton Keynes, Bedfordshire and Luton areas related to concomitant use of high dose and combination gabapentinoids and opioids. ”

    Source location

    Jacqueline Sharman CAMPBELL · Prevention of Future Deaths report
    Page 2 · concerns

    Open source report

    Source evidence

    How this respondent action was interpreted

    PFD Monitor created a concise, searchable interpretation from the published response wording shown below.

    PFD Monitor interpretation

    Audit high-dose opioid patients, arrange reviews, and consider dose reduction where appropriate.

    Verbatim wording from the response

    “2) In March 2022 we carried out an audit of patients on high dose opioids (> 120mg oral morphine equivalent) and arranged a review of these patients. We repeated this Audit in November- December 2022 and are currently in the process of redoing this audit and consideration given to dose reduction where appropriate.”

    Source location

    Response from Hilltop Surgery
    Page 1 · response
    Published 28 February 2023

    Open published response

    Source evidence

    How this respondent action was interpreted

    PFD Monitor created a concise, searchable interpretation from the published response wording shown below.

    PFD Monitor interpretation

    Identify and review patients prescribed opioids with gabapentinoids and benzodiazepines or Z-drugs.

    Verbatim wording from the response

    “4) We have identified other patients on combination of Opiates+Gabapentinoids+Benzodiazepines/Z-drugs who have now been reviewed.”

    Source location

    Response from Hilltop Surgery
    Page 1 · response
    Published 28 February 2023

    Open published response

    Source evidence

    How this respondent action was interpreted

    PFD Monitor created a concise, searchable interpretation from the published response wording shown below.

    PFD Monitor interpretation

    Maintain three-monthly medication reviews using recall systems, preferably face to face and with a named clinician.

    Verbatim wording from the response

    “5) We are ensuring that these patients are reviewed 3 monthly, with robust recall systems in place, preferably face to face and with named clinician to review and rationalise the medication.”

    Source location

    Response from Hilltop Surgery
    Page 1 · response
    Published 28 February 2023

    Open published response

    Source evidence

    How this respondent action was interpreted

    PFD Monitor created a concise, searchable interpretation from the published response wording shown below.

    PFD Monitor interpretation

    Use the Arden’s Opioid Initiation and Monitoring template during medication reviews.

    Verbatim wording from the response

    “7) We have discussed and agreed that patients on a combination of Opiates+gabapentinoids+Benzodiazepines/Z drugs are reviewed 3 monthly and patients on high dose Opioids are reviewed 6 monthly. We agreed to use the Arden’s ‘Opioid Initiation and Monitoring’ template during the reviews to ensure all areas of review are covered.”

    Source location

    Response from Hilltop Surgery
    Page 1 · response
    Published 28 February 2023

    Open published response

    Source evidence

    How this respondent action was interpreted

    PFD Monitor created a concise, searchable interpretation from the published response wording shown below.

    PFD Monitor interpretation

    Operate a national programme to reduce harm from high-dose opioids prescribed for non-cancer pain.

    Verbatim wording from the response

    “The NHS Medicines Safety Improvement Programme (which forms a key part of the NHS Patient Safety Strategy) has launched a focussed programme of work to improve the care of people with chronic pain and a reduction in the use of prescribed opioids by aiming to reduce harm from opioid medicines by reducing high dose prescribing”

    Source location

    Response from NHS England
    Page 1 · response
    Published 28 February 2023

    Open published response

    Source evidence

    How this respondent action was interpreted

    PFD Monitor created a concise, searchable interpretation from the published response wording shown below.

    PFD Monitor interpretation

    Support Integrated Care Systems to develop, implement, adapt and share effective improvements in chronic pain and opioid prescribing care.

    Verbatim wording from the response

    “(>120mg oral Morphine equivalent), for non-cancer pain by 50%, by March 2024. The programme has been in place since January 2021. The national programme is supporting Integrated Care Systems to learn from, adapt and adopt effective practice using a whole-system improvement approach.”

    Source location

    Response from NHS England
    Page 2 · response
    Published 28 February 2023

    Open published response

    Source evidence

    How this respondent action was interpreted

    PFD Monitor created a concise, searchable interpretation from the published response wording shown below.

    PFD Monitor interpretation

    Develop national resources supporting consistent repeat-prescribing processes and structured medication reviews for patients at risk from multiple medicines.

    Verbatim wording from the response

    “The National overprescribing review report commissioned by DHSC in 2018 evaluated the extent, causes and consequences of overprescribing and made 20 recommendations to address it. NHS England aims to make long term sustainable reductions to overprescribing and is working on several outputs to help implement the review’s recommendations. Outputs include national resources to help practices improve the consistency of repeat prescribing processes, supported by appropriate training; and resources to enhance structured medication reviews for patients who may experience harm from taking multiple medicines.”

    Source location

    Response from NHS England
    Page 1 · response
    Published 28 February 2023

    Open published response

    Source evidence

    How this respondent action was interpreted

    PFD Monitor created a concise, searchable interpretation from the published response wording shown below.

    PFD Monitor interpretation

    Publish a national framework to help systems improve personalised care for adults prescribed dependence- or withdrawal-associated medicines.

    Verbatim wording from the response

    “In March 2023, NHS England published ‘Optimising personalised care for adults prescribed medicines associated with dependence or withdrawal symptoms: Framework for action for ICBs and primary care’. The framework includes five actions, resources, and case studies to help systems develop plans that can support people who are taking medicines associated with dependence and withdrawal symptoms by:”

    Source location

    Response from NHS England
    Page 2 · response
    Published 28 February 2023

    Open published response

  4. Inner North London

    AI-generated summary

    Kenneth John Daly · Prevention of Future Deaths report

    This summary was generated using AI from the published report. Please read the original report for the complete account.

    Report summary

    Kenneth John Daly, who had chronic pain and anxiety and was prescribed multiple medications, was found dead at home on 4 December 2018. The inquest concluded that his death was drug related, involving multi-drug toxicity, after he overdosed on Morphine, Dihydrocodeine and Codeine alongside Pregabalin and benzodiazepine medication. Concerns included unclear guidance about using multiple opioid medications together and the absence of tailored written advice for Mr Daly.

    Read the report on judiciary.uk

    Source evidence

    How this individual concern was interpreted

    PFD Monitor created a concise, searchable interpretation from the report wording shown below.

    PFD Monitor interpretation

    Lack of written advice on the risks of combining multiple opioids

    Wider context from the report

    “1) In oral evidence, the Consultant stated that no other opioids were to be taken once Morphine Sulphate and Co-Codamol had been prescribed but that prescribing of Pregabalin could continue. She set out her advice in a letter to Mr Daly’s GP dated 11 July 2018. The letter clearly stated that Fentanyl and Tapentadol should be stopped and Morphine sulphate (MST) 60mg started. The advice regarding the prescribing of pain relieving medications other than Fentanyl and Tapentadol is less clear. In relation to Dihydrocodeine and Tramadol it is stated that “He can continue using the Dihydrocodeine and very rarely Tramadol until he sees you for his next prescription. Together with the MST, I would recommend to allow him Co-Codamol 30/500mg 2 tablets up to four times a day...”. Following receipt of the letter, Tramadol and Dihydrocodeine continued to be issued by the GP practice albeit at lower quantities than previously prescribed. The GP did not seek any further guidance regarding the advice given in the letter of 11 July 2018 from the Consultant. 2) Mr Daly was a patient that was known to adjust his pain medication without seeking guidance from his GP. Whilst Mr Daly was copied in to the letter sent to his GP on 11 July 2018, he was not given any written guidance regarding his pain relief and the use of other medications (such as benzodiazepines) that was tailored to his needs as a patient. Specifically, he was not given any written advice regarding the risks of using multiple opioid medications in combination. ”

    Source location

    Kenneth John Daly · Prevention of Future Deaths report
    Page 4 · concerns

    Open source report

  5. Manchester North

    AI-generated summary

    Ian Paul Wolstenholme · Prevention of Future Deaths report

    This summary was generated using AI from the published report. Please read the original report for the complete account.

    Report summary

    Ian Paul Wolstenholme was found collapsed at home on 17 December 2017 and died later that day. The medical cause of death was combined drug toxicity, with liver cirrhosis and diabetes mellitus also contributing. The report raised concern about the lack of guidance for prescribing highly addictive and potentially harmful drugs together, particularly in cases of polypharmacy.

    Read the report on judiciary.uk

    Source evidence

    How this individual concern was interpreted

    PFD Monitor created a concise, searchable interpretation from the report wording shown below.

    PFD Monitor interpretation

    Potential for serious harm or death from combined drug toxicity associated with polypharmacy

    Wider context from the report

    “1. During the course of the evidence, it became apparent that there is no guidance – national or otherwise - available to Clinicians such as GPs, Hospital doctors etc. on the how best to approach the prescribing of highly addictive and potentially very harmful drugs alongside one another. In this case, the deceased had been legitimately prescribed three different types of neuropathic analgesia (including Pregabalin), alongside other opiate based medications. Whilst such drugs are almost always prescribed for very good clinical reason/s, this type of polypharmacy gives rise to the potential risk of serious harm/death. I believe that guidance would help to prevent future deaths from combined drug toxicity. ”

    Source location

    Ian Paul Wolstenholme · Prevention of Future Deaths report
    Page 2 · concerns

    Open source report
Back to top

Data last updated 7 September 2026